A securities class action has been filed against Regenxbio Inc. on behalf of investors who bought its securities between Feb. 9, 2022 and Jan. 27, 2026. The suit alleges the company made false or misleading statements and concealed adverse information about the efficacy and safety of its RGX-111 gene therapy program for Hurler syndrome, and that investors suffered losses when the alleged issues became public. An April 14, 2026 deadline has been set for motions to seek lead plaintiff status.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602252153NEWSFILECNPR____20260225_285303_1) on February 26, 2026, and is solely responsible for the information contained therein.